These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

833 related articles for article (PubMed ID: 33371846)

  • 1. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
    Xu J; Xue Y; Zhou R; Shi PY; Li H; Zhou J
    Med Res Rev; 2021 May; 41(3):1375-1426. PubMed ID: 33277927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far.
    Khan M; Adil SF; Alkhathlan HZ; Tahir MN; Saif S; Khan M; Khan ST
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.
    Aherfi S; Pradines B; Devaux C; Honore S; Colson P; Scola B; Raoult D
    Future Microbiol; 2021 Nov; 16():1341-1370. PubMed ID: 34755538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valinomycin as a potential antiviral agent against coronaviruses: A review.
    Zhang D; Ma Z; Chen H; Lu Y; Chen X
    Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.
    Bolinger AA; Li J; Xie X; Li H; Zhou J
    Expert Opin Drug Discov; 2024 Sep; 19(9):1023-1041. PubMed ID: 39078037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alkaloids: Therapeutic Potential against Human Coronaviruses.
    Fielding BC; da Silva Maia Bezerra Filho C; Ismail NSM; Sousa DP
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33255253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives for repurposing drugs for the coronavirus disease 2019.
    Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
    Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
    Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human and novel coronavirus infections in children: a review.
    Rajapakse N; Dixit D
    Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
    Tarighi P; Eftekhari S; Chizari M; Sabernavaei M; Jafari D; Mirzabeigi P
    Eur J Pharmacol; 2021 Mar; 895():173890. PubMed ID: 33482181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cell receptors: potential drug targets to combat COVID-19.
    Raghav PK; Kalyanaraman K; Kumar D
    Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.
    Wu Z; Harrich D; Li Z; Hu D; Li D
    Rev Med Virol; 2021 Mar; 31(2):e2171. PubMed ID: 33350025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.
    Yang Y; Cui X; Wei H; Guo C; Zhang Y
    Drug Des Devel Ther; 2021; 15():1213-1223. PubMed ID: 33762818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.